Regulatory Network in Protein Phosphorylation
[Home] [About] [Browse Kinome] [Phosphorylation Prediction] [Expression Analysis] [Statistics] [Help] Version 1.0

[Back to Kinase CK2a1]
Substrate: MAPK9

Description: Mitogen-activated protein kinase 9 (EC (Stress-activatedprotein kinase JNK2) (c-Jun N-terminal kinase 2) (JNK-55).

Synonyms: JNK2, PRKM9

Ensembl ID: ENSG00000050748

UniprotKB/SwissProt: MK09_HUMAN (P45984)

Function: Responds to activation by environmental stress and pro- inflammatory cytokines by phosphorylating a number of transcription factors, primarily components of AP-1 such as c-Jun and ATF2 and thus regulates AP-1 transcriptional activity. In T- cells, JNK1 and JNK2 are required for polarized differentiation of T-helper cells into Th1 cells. JNK2 isoforms display different binding patterns: alpha- 1 and alpha-2 preferentially bind to c-Jun, whereas beta-1 and beta-2 bind to ATF2. However, there is no correlation between binding and phosphorylation, which is achieved at about the same efficiency by all isoforms. JUNB is not a substrate for JNK2 alpha-2, and JUND binds only weakly to it.

Other Modifications: View all modification sites in dbPTM

Protein Subcellular Localization:
Protein Domain and Phosphorylation Sites:

The phosphorylated sites of MAPK9

No.SubstrateUniProtKB IDPositionPhosphoPeptideSolvent AccessibilityCatalytic kinaseSourceComputational Annotation of Catalytic KinaseInteracting PartnersExpression Analysis
1MAPK9MK09_HUMANT183TNFMM T PYVVT 10.32% Swiss-Prot 55.0 View   
2MAPK9MK09_HUMANT183TNFMM T PYVVT 10.32%MAP2K7 Phospho.ELM 7.0  ViewAnalyzing
3MAPK9MK09_HUMANT183TNFMM T PYVVT 10.32%MAP2K7 HPRD:04206(in vitro)  ViewAnalyzing
4MAPK9MK09_HUMANY185FMMTP Y VVTRY 9.82%MAP2K4 HPRD:04206(in vitro;in vivo)  ViewAnalyzing
5MAPK9MK09_HUMANY185FMMTP Y VVTRY 9.82%MAP2K4 Phospho.ELM 7.0  ViewAnalyzing
6MAPK9MK09_HUMANY185FMMTP Y VVTRY 9.82%RET HPRD:04206(in vitro)  ViewAnalyzing
7MAPK9MK09_HUMANY185FMMTP Y VVTRY 9.82%MAP2K7 HPRD:04206(in vitro;in vivo)  ViewAnalyzing
8MAPK9MK09_HUMANY185FMMTP Y VVTRY 9.82% Swiss-Prot 55.0 View   
9MAPK9MK09_HUMANT404MSTEQ T LASDT 20.33%MAP2K_group Phospho.ELM 7.0 ViewAnalyzing
10MAPK9MK09_HUMANT404MSTEQ T LASDT 20.33%MAP2K7 HPRD:04206(in vitro)  ViewAnalyzing
11MAPK9MK09_HUMANT404MSTEQ T LASDT 20.33%CK2a1(CK2 alpha) Phospho.ELM 7.0 ViewAnalyzing
12MAPK9MK09_HUMANT404MSTEQ T LASDT 20.33%MAP2K7 Phospho.ELM 7.0  ViewAnalyzing
13MAPK9MK09_HUMANS407EQTLA S DTDSS 44.12%CK2a1(CK2 alpha) Phospho.ELM 7.0 ViewAnalyzing
14MAPK9MK09_HUMANS407EQTLA S DTDSS 44.12%MAP2K7 HPRD:04206(in vitro)  ViewAnalyzing
15MAPK9MK09_HUMANS407EQTLA S DTDSS 44.12%MAP2K7 Phospho.ELM 7.0  ViewAnalyzing
16MAPK9MK09_HUMANS407EQTLA S DTDSS 44.12%MAP2K_group Phospho.ELM 7.0 ViewAnalyzing